32 results
Thumbnail

D1.33 - Patient-reported outcomes following beta-lactam antibiotic allergy delabeling work-up

Thumbnail

D1.34 - Guideline adherence and safety of AI chatbots in allergology

Thumbnail

D1.37 - Which Came First? Atopic Dermatitis or occupational Allergic Contact Dermatitis in a Surgeon with Tropomyosin-Driven IgE Cross-Reactivity

Thumbnail

D1.38 - A Generalizable High-Throughput Nanobody Discovery Platform for Airborne Allergens

Thumbnail

D1.39 - Oral Lichenoid Lesions Secondary to Contact Allergy to L-Carvone from Toothpaste: A Case Report

Thumbnail

D1.40 - Independent Sensitization to poultry meat and tuna in a food allergic young girl

Thumbnail

D1.41 - B cell responses to alarmins in type 2 inflammation

Thumbnail

D1.42 - Unusual Delayed Hypersensitivity Reaction to Different Antibiotic Families

Thumbnail

D1.44 - Primary care allergy and clinical immunology fellowship: A Delphi study of core competencies

Thumbnail

D1.45 - Selective Anaphylaxis to Salmonids with Tolerance to Other Fish

Thumbnail

D2.245 - Dithranol loaded Dendritic nanoarchitectures for the treatment of psoriasis

Thumbnail

D2.246 - Occupational contact dermatitis to chromium in guitarist

Thumbnail

D2.247 - Vitamin D Status as a Modifiable Factor in Chronic Spontaneous Urticaria

Thumbnail

D2.249 - The impact of the coronavirus infection and vaccination against SARS-CoV-2 in the course of chronic urticaria

Thumbnail

D2.251 - Allergic Contact Dermatitis to Clonidine Transdermal Patch: Insights From a Rare Case With Prolonged Cutaneous Exposure

Thumbnail

D2.254 - Thyroid Autoantibody Seroconversion in Chronic Spontaneous Urticaria: Insights from Omalizumab Treated Patients

Thumbnail

D2.255 - Adult-onset Still’s disease mimicking chronic spontaneous urticaria: a case report

Thumbnail

D2.259 - Beyond Contact with Water: A Case of Aquagenic Urticaria

Thumbnail

D2.250 - Sensitivity to Dental Materials and Its Clinical Implications: A Retrospective Patch Test Study

Thumbnail

D2.248 - Asthma control in patients with moderate-to-severe atopic dermatitis and comorbid-asthma treated with lebrikizumab in a real-world-setting: interim analysis of the non-interventional study ADLife